Daratumumab for refractory immune-mediated thrombotic thrombocytopenic purpura.

Aggarwal A., White D., Pavord S., Thomas W., Desborough MJR.

DOI

10.1111/bjh.18854

Type

Journal article

Publication Date

2023-07-01T00:00:00+00:00

Volume

202

Pages

429 - 433

Total pages

4

Keywords

daratumumab, plasma cell, refractory, thrombotic thrombocytopenic purpura (TTP), Humans, Purpura, Thrombotic Thrombocytopenic, Antibodies, Monoclonal, Rituximab, Plasma Exchange

Permalink More information Close